Federal Circuit Panel Deliberates Validity of Johnson & Johnson Schizophrenia Medication Patent

In a recent session, a Federal Circuit panel examined the complexities surrounding the validity of a dosage patent associated with Johnson & Johnson’s popular schizophrenia medication, Invega Sustenna. The debate centered on whether the patent should be declared invalid due to obviousness. Attorneys from both Johnson & Johnson and Teva Pharmaceuticals were pressed to clarify their analyses regarding the patent’s legitimacy. The outcome of this dispute could significantly impact the pharmaceutical market landscape, especially concerning generic drug availability. For further details on this unfolding case, visit Law360.